Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 136

Results For "LA"

8967 News Found

Lupin launches Rocuronium Bromide injection in US
Drug Approval | November 09, 2023

Lupin launches Rocuronium Bromide injection in US

Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).


Biocon Biologics announces divestment of two non-core branded formulations
News | November 09, 2023

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million


Evonik launches GMP-quality plant-based squalene
News | November 08, 2023

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use


Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr
News | November 07, 2023

Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr

Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023


Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr
News | November 07, 2023

Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr

Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023


Henkel launches new medical grade wearables device light cure adhesives
News | November 04, 2023

Henkel launches new medical grade wearables device light cure adhesives

The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h


Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs
News | November 03, 2023

Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs

Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023


Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr
News | November 03, 2023

Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023


Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr
News | November 03, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023


Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
Digitisation | November 03, 2023

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists